Albumin-bound paclitaxel, approved by the US FDA for the first-line treatment of non-small cell lung cancer (3), breast cancer (4), ovarian cancer (5), and pancreatic cancer (6), has been demonstrated to simplify pre-treatments and reduce allergic events during chemotherapy. The gene discussed is ALB; the disease is ovarian carcinoma.